As promised in my 67th AAD Meeting SFO, rosacea highlights news item, here are some updates from the conference proceedings and handouts. In this update we’ll look at a couple of slides from Dr. Thiboutot.
I found it very encouraging to see such an up to date list of possibilities being discussed at an AAD forum.
Of course only being able to read the slides doesn’t compare to actually attending, but nonetheless it is still an encouraging sign that this level of forward looking is permeating the ranks of dermatologists.
FRM F013, Problem Cases of Rosacea, Diane M. Thiboutot, M.D., Professor of Dermatology, The Pennsylvania State University, College of Medicine, Hershey, PA.
Dr. Thiboutot notes that she is a clinical trials investigator and consultant to Galderma and Intendis. Also investigator or consultant to Allergan, Arcutis, Obagi and Stiefel.
Slide 23: Agents reported (off-label) in rosacea
- Oral ivermectin
- Topical permethrin
- Topical pimecrolimus
- Photodynamic therapy (methyl ALA/red light)
- Azithromycin
- Oxymetazoline (a1 adrenergic agonist)
Slide 25: Possible future treatments
- Improved laser/light protocols
- Agents for erythema
- Topical ivermectin
- Topical dapsone
- Agents targeting cathelicidin peptides/kallikrein protease inhibitors
Related Articles
- sansrosa news and updates.
- demodex mites, ivermectin (stromectol) and its use in dermatology
- demodex mites ivermectin effective treatment ?
- Ivermectin: Supplements & Resources
- oxymetazoline good for 6 hours and safe for 3 months
- aczone (topical dapsone) recruiting trial participants
